Nektar Q1 net loss narrows to $36.8M; REZPEG Phase 2b on track for H1 2025 data

NEKTAR THERAPEUTICS

2024-Q1 EPS reported -$0.19 revenue$21,639,000

Revenue flat at $21.6M; net loss of $36.8M ($0.19/share) vs $137M loss YoY, improved on lower costs.
Cash and securities $326M; expects to fund operations into Q3 2026.
R&D expense $27.4M, down from $30.5M YoY; G&A $20.1M vs $21.1M.
Phase 2b REZPEG studies in atopic dermatitis and alopecia areata enrolling; topline data H1 2025.
Raised $30M gross via private placement in March 2024 with TCG Crossover Fund.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

NEKTAR THERAPEUTICS reported first quarter ended March 31, 2024 results: revenue $21.6 million, net income $36.8 million or $0.19 basic and diluted loss per share, EPS $0.19 basic and diluted loss per share.

Period: first quarter ended March 31, 2024
Revenue: $21.6 million
Net income: $36.8 million or $0.19 basic and diluted loss per share
EPS: $0.19 basic and diluted loss per share
Result: reported results

Exact text from the filing

the TNFR2 receptor is progressing through IND-enabling studies to support entering the clinic next year.” Summary of Financial Results Revenue in the first quarter of 2024 was $21.6 million as compared to the same $21.6 million in the first quarter of 2023. Total operating costs and expenses in the first quarter of 2024 were $57.1 million as compared to $156.3

View on SEC.gov

1050 earnings releases filed in the last 30 days. Browse all earnings releases →

NEKTAR THERAPEUTICS filing history →

Source: SEC EDGAR

accession 0001213900-24-041325

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.